New York, USA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Allogeneic Hematopoietic Stem Cell Transplant Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight The allogeneic hematopoietic stem cell transplant market is expected to experience significant growth in the coming years, driven by advances in transplantation techniques, improved donor-matching technologies, and a rising incidence of hematological malignancies. Increased awareness of the therapeutic potential of stem cell transplants, along with ongoing research into novel conditioning regimens and post-transplant care, will further boost market expansion.
DelveInsight’s Allogeneic Hematopoietic Stem Cell Transplant Market Insights report includes a comprehensive understanding of current treatment practices, emerging allogeneic HSCT drugs, market share of individual therapies, and current and forecasted allogeneic HSCT market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the Allogeneic Hematopoietic Stem Cell Transplant Market Report According to DelveInsight’s analysis, the market size of allogeneic HSCT in the 7MM is expected to grow at a significant CAGR by 2034. According to DelveInsight’s estimates, the United States accounted for the highest number of cases of allo-HSCT among the 7MM, in 2023.
In 2023, the type-specific cases of HSCT in the United States were over 10,000 and 14,500 .
